Kaplan-Meier analysis examining the effect of TET2 or IDH1/2 mutations in patients with NPM1-mutated AML who received standard induction chemotherapy. All analyses included patients who received standard induction chemotherapy (n = 172 in total). (A-B) The presence of TET2 or IDH1/2 mutations had no effect on RFS (A) or OS (B) when examining the entire cohort of AML-NPM1s (RFS, 17.4 months; OS, 37.8 months for patients with TET2/IDH mutations [n = 96] vs RFS, 15.2 months; OS, 44.3 months for patients without TET2/IDH mutations [n = 80]). (C-D) In patients with monocytic AML-NPM1, TET2 and IDH1/2 comutations (n = 35) were associated with shortened RFS (13.8 vs 32.3 months in patients without TET2/IDH comutations [n = 42]; P = .026) (C) and OS (38.1 vs 88.4 months in patients without TET2/IDH comutations) (D).